ABCB1 and ovarian carcinoma: Understanding which primary and second-line treatments are MDR1 substrates, the conflicting substrates and pharmacokinetics of MDR1 and CYP enzymes, and shared mechanisms of resistance in multiple chemotherapeutic drugs will help to overcome one of the mechanisms of taxane resistance in ovarian cancer.